celecoxib has been researched along with Non-alcoholic Fatty Liver Disease in 5 studies
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) is a kind of liver lipid synthesis and degradation imbalance related with metabolic syndrome." | 5.48 | Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. ( He, XX; Li, PY; Liao, JZ; Liu, C; Liu, L; Sheng, JQ; Tian, DA; Wu, XL; Zhu, HD, 2018) |
| "Nonalcoholic fatty liver disease (NAFLD) is a kind of liver lipid synthesis and degradation imbalance related with metabolic syndrome." | 1.48 | Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. ( He, XX; Li, PY; Liao, JZ; Liu, C; Liu, L; Sheng, JQ; Tian, DA; Wu, XL; Zhu, HD, 2018) |
| "Celecoxib treatment may be a favorable treatment option for NASH." | 1.43 | Suppressing cyclooxygenase-2 prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway. ( Cai, B; Cai, X; Chen, C; Chen, X; Guan, Y; Hu, H; Hu, X; Jing, X; Wang, Q; Wu, J, 2016) |
| "The underlying mechanisms of nonalcoholic steatohepatitis (NASH) are poorly understood, and little is known about hepatocellular apoptosis in NASH." | 1.39 | Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats. ( Chen, M; Cheng, Q; Huang, C; Li, N; Qian, Z; Shi, G; Wang, X; Xu, S; Zheng, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, C | 1 |
| Lu, Y | 1 |
| Song, Y | 1 |
| Chen, L | 1 |
| Hu, J | 1 |
| Meng, Y | 1 |
| Chen, X | 2 |
| Li, S | 1 |
| Zheng, G | 1 |
| Qiu, Z | 1 |
| Liu, C | 1 |
| Liu, L | 1 |
| Zhu, HD | 1 |
| Sheng, JQ | 1 |
| Wu, XL | 1 |
| He, XX | 1 |
| Tian, DA | 1 |
| Liao, JZ | 1 |
| Li, PY | 1 |
| Cheng, Q | 1 |
| Li, N | 1 |
| Chen, M | 1 |
| Zheng, J | 1 |
| Qian, Z | 1 |
| Wang, X | 1 |
| Huang, C | 1 |
| Xu, S | 1 |
| Shi, G | 1 |
| Tian, F | 1 |
| Zhang, YJ | 1 |
| Li, Y | 1 |
| Xie, Y | 1 |
| Wu, J | 1 |
| Chen, C | 1 |
| Hu, X | 1 |
| Cai, X | 1 |
| Guan, Y | 1 |
| Hu, H | 1 |
| Wang, Q | 1 |
| Cai, B | 1 |
| Jing, X | 1 |
5 other studies available for celecoxib and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.
Topics: Animals; Celecoxib; Fructose; Humans; Insulins; Lipogenesis; Liver; Mice; Non-alcoholic Fatty Liver | 2022 |
Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux.
Topics: Animals; Autophagy; Celecoxib; Cell Line; Chloroquine; Diet, High-Fat; Humans; Male; Non-alcoholic F | 2018 |
Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diet, High-Fat; Diseas | 2013 |
Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression.
Topics: Animals; Biomarkers; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Ty | 2014 |
Suppressing cyclooxygenase-2 prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway.
Topics: Animals; Apoptosis; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; DNA-B | 2016 |